Personal Capital Advisors Corp Biogen Inc. Transaction History

Personal Capital Advisors Corp

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$223.92 - $287.77 $165,476 - $212,662	-739 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$282.99 - $369.05 $3,678 - $4,797	13 Added 1.79%	739 $209,000
Q2 2021 Aug 11, 2021	SELL	$259.0 - $414.71 $4,144 - $6,635	-16 Reduced 2.16%	726 $251,000
Q1 2021 May 14, 2021	BUY	$242.95 - $284.63 $180,268 - $211,195	742 New	742 $208,000
Q4 2020 Feb 12, 2021	SELL	$236.26 - $355.63 $196,095 - $295,172	-830 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$264.77 - $305.71 $10,590 - $12,228	40 Added 5.06%	830 $235,000
Q2 2020 Aug 12, 2020	SELL	$258.66 - $342.55 $4,655 - $6,165	-18 Reduced 2.23%	790 $211,000
Q1 2020 May 12, 2020	SELL	$268.85 - $341.04 $33,068 - $41,947	-123 Reduced 13.21%	808 $255,000
Q4 2019 Feb 13, 2020	SELL	$220.06 - $304.07 $33,449 - $46,218	-152 Reduced 14.04%	931 $276,000
Q3 2019 Nov 07, 2019	BUY	$217.44 - $243.88 $2,174 - $2,438	10 Added 0.93%	1,083 $252,000
Q2 2019 Aug 14, 2019	BUY	$219.29 - $241.72 $13,815 - $15,228	63 Added 6.24%	1,073 $251,000
Q1 2019 May 13, 2019	BUY	$216.71 - $338.96 $218,877 - $342,349	1,010 New	1,010 $239,000

1,037

126M

1.13M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.5B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Personal Capital Advisors Corp, based on Form 13F filings with the SEC.

Stay updated on Personal Capital Advisors Corp with notifications on news.